An Open-Label Phase I Dose-Escalation Study of Sorafenib Plus S-1 in Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2016
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 16 Oct 2015 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record.
- 14 Aug 2012 Planned End Date changed from 1 Oct 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 14 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.